Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia
Authors:
- 1 August 2009
- journal article
- clinical trial
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 24 (6) , 447-452
Abstract
Objective To investigate the efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Method Thirty‐nine patients fulfilling DSM‐IV‐TR diagnostic criteria for schizophrenia and had depressive symptoms were studied in a prospective 6‐week open‐label design using quetiapine monotherapy. The brief psychiatric rating scale (BPRS), 17‐item Hamilton depression rating scale (HAMD‐17), Simpson–Angus rating scale, and the Barnes Akathisia rating scale (BARS) were used to assess patients at baseline, week 1, 2, 4, and 6. Results Thirty patients (76.9%) completed this study. The dose of quetiapine at endpoint was 583 (±235 SD) mg/day. Treatment with Quetiapine was associated with significantly reduced depressive symptoms (HAMD‐17 total score and BPRS depression/anxiety subscale) from the first week of treatment. Changes of mean score from baseline to endpoint were 7.8 ± 6.2 for HAMD‐17 total score and 3.4 ± 3.6 for BPRS depression/anxiety subscale (LOCF, n = 39, p < 0.001). Quetiapine was well tolerated, with minimal extrapyramidal symptoms and non‐significant increase in body weight (mean increase of 0.8 kg). Conclusions While the interpretation of findings from the open‐label design of this study warrants appropriate caution, the results suggest that quetiapine may be an effective and tolerable treatment for depression in patients with schizophrenia. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Depression in schizophrenia: Comparison of first- and second-generation antipsychotic drugsSchizophrenia Research, 2007
- Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depressionInternational Journal Of Clinical Practice, 2007
- Quetiapine and Long-Term Weight ChangeThe Journal of Clinical Psychiatry, 2007
- The burden of depressive symptoms in the long-term treatment of patients with schizophreniaSchizophrenia Research, 2007
- Quality of life in schizophrenic patients: Association with depressive symptomsNordic Journal of Psychiatry, 2006
- Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patientsSchizophrenia Research, 2005
- Does Quetiapine Have Mood Altering Properties?Journal of Psychopharmacology, 2004
- Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled TrialNeuropsychopharmacology, 1999
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960